Multicenter Study of Isavuconazole MIC Distributions and Epidemiological Cutoff Values for Aspergillus spp. for the CLSI M38-A2 Broth Microdilution Method

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 8, 2013, Pages 3823-3828

  Espinel Ingroff, A ^a   Chowdhary, A ^b   Gonzalez, G M ^c   Lass Florl C ^d   Martin Mazuelos, E ^e   Meis, J ^f,g   Pelaez T ^h   Pfaller, M A ⁱ   Turnidge, J ^j  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF DELHI   (India)

^c UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^f CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^g RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^h HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

ⁱ JMI LABORATORIES   (United States)

^j UNIVERSITY OF ADELAIDE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ISAVUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; ASPERGILLUS VERSICOLOR; BROTH DILUTION; CONTROLLED STUDY; EPIDEMIOLOGICAL CUTOFF VALUE; EUROPE; FUNGUS MUTATION; GROWTH INHIBITION; INDIA; MEXICO; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; UNITED STATES; WILD TYPE;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, FUNGAL; FUNGAL PROTEINS; GENES, FUNGAL; GEOGRAPHY; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; NITRILES; PYRIDINES; PYRIMIDINES; REFERENCE VALUES; TRIAZOLES;

EID: 84880255910     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00636-13     Document Type: Article

References (43)

1. Barnes PD, Marr KA. 2006. Aspergillosis: spectrum of disease, diagnosis, and treatment. Infect. Dis. Clin. North Am. 20:545-561.
2. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. 2008. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin. Infect. Dis. 47:1041-1050.
3. Kaya AD, Kiraz N. 2007. In vitro susceptibilities of Aspergillus spp. causing resistance otomycosis to amphotericin B, voriconazole and itraconazole. Mycoses 50:447-450.
4. Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, Pfaller M, Chang C, Webster K, Marr K. 2009. Epidemiology and outcome of invasive fungal infections in adult hematopoietic stem cell transplant recipients: analysis of multicenter PATH Alliance Registry. Clin. Infect. Dis. 48:265-273.
5. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
6. Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E, Brown T, Roehrle M, Beglinger C. 2006. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob. Agents Chemother. 50:279-285.
7. Thompson GR, III, Wiederhold NP. 2010. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 170: 291-313.
8. Warn PA, Sharp A, Parmar A, Majithiya J, Denning DW, Hope WW. 2009. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob. Agents Chemother. 51:3453-3461.
9. Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. 2008. In vitro antifungal activities of isavuconazole (BAL-4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob. Agents Chemother. 52: 1396-1400.
10. Perkhofer S, Lechner V, Lass-Florl C. 2009. In vitro activity of isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 53:1645-1647.
11. Seifert H, Aurbach U, Stefanik D, Cornely O. 2007. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob. Agents Chemother. 51:1818-1821.
12. Rudramurthy SM, Chakrabarti A, Geertsen E, Mouton JW, Meis JF. 2011. In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Diagn. Microbiol. Infect. Dis. 71:370-377.
13. Warn PA, Sharp A, Mosquera J, Spickermann J, Schmitt-Hoffmann A, Heep M, Denning DW. 2006. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557 in a neutropenic murine model of disseminated Aspergillus flavus. J. Antimicrob. Chemother. 58: 1198-1207.
14. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. 2012. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J. Antimicrob. Chemother. 67:362-366.
15. Camps SMT, van der Linden JWM, Li Y, Kuijper EJ, van Dissel JT, Verweij PE, Melchers WJ. 2012. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob. Agents Chemother. 56:10-16.
16. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, Laverdiere M, Arendrup MC, Perlin DS, Denning DW. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
17. Klaassen CHW, de Valk HA, Curfs-Breuker IM, Meis JF. 2010. Novel mixed-format real-time PCR assay to detect mutations conferring resistance to triazoles in Aspergillus fumigatus and prevalence of multi-triazole resistance among clinical isolates in the Netherlands. J. Antimicrob. Chemother. 65:901-905.
18. Mavridou E, Bruggemann RJM, Melchers WJG, Mouton JW, Verweij PE. 2010. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob. Agents Chemother. 54:860-865.
19. van der Linden JWM, Jansen RR, Bresters D, Visser CE, Geerlings SE, Kuijper EJ, Melchers WJG, Verweij PE. 2009. Azole-resistant central nervous system aspergillosis. Clin. Infect. Dis. 48:1111-1113.
20. van der Linden JWM, Snelders E, Kampinga GA, Rijnders BJA, Mattsson E, Debets-Ossenkopp YJ, Kuijper EJ, Van Tiel FH, Melchers WJG, Verweij PE. 2011. Clinical implications of azole resistance in Aspergillus fumigatus, the Netherlands, 2007-2009. Emerg. Infect. Dis. 17: 1846-1854.
21. Balajee SA, Brandt ME. 2011. Aspergillus and Penicillium: mycology, p 1836-1852. In Versalovic J, Carroll KC, Jorgensen JH, Funke G, Landry ML, Warnock DW (ed), Manual of clinical microbiology, 10th ed, vol2. ASM Press, Washington, DC.
22. Staab JF, Balajee SA, Marr KA. 2009. Aspergillus section Fumigati typing by PCR-restriction fragment polymorphism. J. Clin. Microbiol. 47:2079-2083.
23. Balajee SA, Borman AM, Brandt ME, Cano J, Cuenca-Estrella M, Dannaoui E, Guarro J, Haase G, Kibbler CC, Meyer W, O'Donnell K, Petti CA, Rodríguez-Tudela JL, Sutton D, Velegraki A, Wickes BL. 2009. Sequence-based identification of Aspergillus, Fusarium, and Mucorales species in the clinical mycology laboratory: where are we and where should we go from here?. J. Clin. Microbiol. 47:877-884.
24. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
25. Clinical and Laboratory Standards Institute. 2013. Minutes and agenda: annual meeting of the Subcommittee for Antifungal Susceptibility Testing, Tampa, FL, 22 January 2013. Clinical and Laboratory Standards Institute, Wayne, PA.
26. Turnidge J, Paterson DL. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin. Microbiol. Rev. 20:391-408.
27. Espinel-Ingroff A, Diekema DJ, Fothergill A, Johnson E, Pelaez T, Pfaller M, Rinaldi MG, Canton E, Turnidge J. 2010. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2). J. Clin. Microbiol. 48:3251-3257.
28. Espinel-Ingroff A, Fothergill A, Fuller J, Johnson E, Pelaez T, Rinaldi MG, Turnidge J. 2011. Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob. Agents Chemother. 55:2855-2859.
29. Espinel-Ingroff A, Cuenca-Estrella M, Fothergill A, Fuller J, Ghannoum M, Johnson E, Pelaez T, Pfaller MA, Turnidge J. 2011. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob. Agents Chemother. 55:5150-5154.
30. Turnidge J, Kahlmeter G, Kronvall G. 2006. Statistical characterization of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin. Microbiol. Infect. 12:418-425.
31. Turnidge J, Bordash G. 2007. Statistical methods for establishing quality control limits in Clinical and Laboratory Standards Institute susceptibility testing. Antimicrob. Agents Chemother. 51:2483-2488.
32. Dalhoff A, Ambrose PG, Mouton JW. 2009. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection 37:296-305.
33. Verweij PE, van den Bergh MFQ, Rath PM, dePaw BE, Voss A, Meis JF. 1999. Invasive aspergillosis caused by Aspergillus ustus: case report and review. J. Clin. Microbiol. 37:1606-1609.
34. Meletiadis J, Mavridou E, Melchers WJG, Mouton JW, Verweij PE. 2012. Epidemiological cutoff values for azoles and Aspergillus fumigatus based on a novel mathematical approach incorporating cyp51A sequence analysis. Antimicrob. Agents Chemother. 56:2524-2529.
35. Pfaller MA, Diekema DJ, Ghannoum MA, Rex JH, Alexander BD, Andes D, Brown SD, Espinel-Ingroff A, Fowler CL, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Sheehan DJ, Walsh T. 2009. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J. Clin. Microbiol. 47:3142-3146.
36. Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Monson A, Cuenca-Estrella M. 2008. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 52:2468-2472.
37. Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodríguez-Tudela JL. 2009. Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. Antimicrob. Agents Chemother. 53:4514-4517.
38. Espinel-Ingroff A, Cuenca-Estrella M, Canton E. 2013. CLSI and EUCAST: working together towards a harmonized method for antifungal susceptibility testing. Curr. Management Fungal Infect. 7:59-67.
39. Mellado E, Diaz-Guerra TM, Cuenca-Estrella M, Rodriguez-Tudela JL. 2001. Identification of two different 14 sterol demethylase-related genes (cyp51A and cyp51B) inAspergillus fumigatus and other Aspergillus species. J. Clin. Microbiol. 39:2431-2438.
40. Van den Brink HJ, Van Nistelrooy HJ, de Waard MA, van den Hondel CA, van Gorcom RF. 1996. Increased resistance to 14-alpha-demethylase inhibitors (DMIs) in Aspergillus niger by coexpression of the Penicillium italicum eburicol 4-alpha-demethylase (cyp51) and the A. niger cytochrome P450 reductase (cypA). J. Biotechnol. 49:13-18.
41. Arendrup MC, Jensen RH, Grif K, Skov M, Pressler T, Johansen HK, Lass-Flörl C. 2012. In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I alteration. J. Infect. Dis. 206:981-985.
42. Pavie J, Lacroix C, Hermoso DG, Robin M, Ferry C, Bergeron A, Feuilhade M, Dromer F, Gluckman E, Molina J-M, Ribaud P. 2005. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J. Clin. Microbiol. 43:4902-4904.
43. Osherov N, Kontoyannis DP, Romans A, May GS. 2001. Resistance to itraconazole in Aspergillus nidulans and Aspergillus fumigatus is conferred by extra copies of the A. nidulans P-450 14-alpha-demethylase gene, pmdA. J. Antimicrob. Chemother. 48:75-81.